Arca Biopharma (NASDAQ:ABIO) released its earnings results on Thursday. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07, Fidelity Earnings reports.
ABIO stock opened at $0.66 on Friday. Arca Biopharma has a 12 month low of $0.45 and a 12 month high of $2.00.
Separately, ValuEngine raised shares of Arca Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
ARCA biopharma, Inc, a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction.
Featured Article: How do investors use RSI to grade stocks?
Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.